Current medical literature is insufficient to support conclusions concerning efficacy, optimal use and impact on the diagnosis, treatment or clinical management of prostate cancer using radioimmunoscintigraphy imaging with indium-111 capromab pendetide. Indium-111 capromab pendetide (prostascint®) (also referred to as cyt356) targets an intracellular - binding site on prostate-specific membrane antigen (psma) and has been approved by the us food and drug administration (fda) for use as a diagnosing imaging agent in newly diagnosed patients with. 323 prostatic radioimmunoscintigraphy imaging utilizing spect for the following indications: 3231 metastatic spread of prostate cancer and for use in post-prostatectomy patients in whom there is a high suspicion of undetected cancer recurrence. Prostascint is the first and only commercial monoclonal antibody-based agent targeting prostate-specific membrane antigen (psma) to image the extent and spread of prostate cancer.
Prostascint scan for staging prostate cancer prostascint scan for staging prostate cancer lange, paul h 2001-03-01 00:00:00 i agreed to enter a debate siding against the value of indium-111 ( 111 in)-capromab pendetide (cyt-356) (prostascint) imaging with mixed emotions. Ebscohost serves thousands of libraries with premium essays, articles and other content including indium-111 capromab pendetide (prostascintâ®) demonstrates renal cell carcinoma and aortocaval nodal metastases from prostate adenocarcinoma. The most intensively studied monoclonal antibody conjugate to psma is capromab pendetide (prostascint, cytogen corp, princeton, new jersey), which is a 100 kd type ii transmembrane glycoprotein that recognizes an intracellular epitope [49 x  troyer, jk, beckett, ml, and wright, gl jr location of prostate-specific membrane antigen in. Abstract to evaluate whether in-111 capromab pendetide (an antibody conjugate directed to a glycoprotein found primarily on the cell membrane of prostate tissue) radioimmunoscintigraphy can localize residual or metastatic prostatic carcinoma in 15 patients after prostatectomy and lymphadenectomy for prostatic carcinoma with rising serum prostate-specific antigen.
The literature supports the fact that patients with negative pelvic lymph nodes later develop distant metastases3, 4, 13, 14 radioimmunoscintigraphy with indium in-111 capromab pendetide can help detect this and can alert the physician to investigate further. (111)in capromab pendetide (prostascintr) is a whole murine antibody that is reactive with prostate specific membrane antigen (psma), a glycoprotein on the surface of normal and abnormal prostate. The 111 in-capromab pendetide scan, also known as the prostascint® scan (cytogen corporation, princeton, nj) utilizes a radiolabeled monoclonal antibody directed toward an intracellular epitope (n-terminus) of the prostate-specific membrane antigen (psma) molecule 9, 10 psma is a 120-kd transmembrane glycoprotein with unknown physiologic.
A more recent imaging modality is the 111 indium-capromab pendetide scan, known as the prostascint scan this test offers the potential for accurate localization of. Capromab pendetide radiolabeled with indium-111 or prostascint® capromab pendetide radiolabeled with indium-111 was approved 10 years ago by the us food and drug administration for use in imaging soft tissue sites of metastatic prostate cancer for presurgical staging or the evaluation of psa relapse after local therapy. 111 in-capromab pendetide scintigraphy targets a tissue-specific marker (psma) of neoplastic prostate cells, and it uses a stable in vivo immunoconjugate that produces a good target-to-background photon emission (tumor to blood) ratio 33- 38 despite these qualities, inaccuracy of 111 in-capromab pendetide imaging has been reported. Prostascint® vial contains 05 mg of capromab pendetide in 1 ml of sodium phosphate buffered saline solution adjusted to ph 6 a sterile, pyrogen-free, clear, colorless solution that may contain some translucent particles.
Later capromab pendetide studies: con thomas ct, bradshaw pt, pollock bh, et al indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. The limitations of many of the above imaging modalities have motivated the development of radioimmunoscintigraphy (ris) for prostate cancer 20 - 31 the most common type of ris employs capromab pendetide (prostascint, cytogen corporation, princeton, nj), a site-specific murine monoclonal antibody labeled with indium-111 that is reactive with. Molecular imaging with indium 111 (111 in)-capromab pendetide (prostascint eusa pharma, langhorne, pa) is also used to restage recurrent prostate cancer (9,11-14) however, accurate determination of the extent and location of recurrent disease with existing imaging techniques has proved challenging ( 14 , 15 .
111in-capromab pendetide the evolution of prostate specific membrane antigen and the nuclear imaging of its 111in-labelled murine antibody in the evaluation of prostate cancer. Prostascint, a monoclonal antibody (capromab pendetide) combined with radioactive indium-111, is used to detect prostate cancer it is injected into the body and a gamma camera (designed to detect radioactivity) is then used to locate prostate cancer cells. Radioimmunoscintigraphy using indium-111 capromab pendetide (prostascint®) is considered investigational for the evaluation and management of individuals with prostate cancer. Capromab pendetide radioimmunoscintigraphy and prognosis 6 patel a, dorey f, franklin j, et al recurrence patterns after for durable biochemical response to salvage radiation therapy radical retropubic prostatectomy: clinical usefulness of pros- in men after failed prostatectomy.